# A Study of Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT00988858** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 55 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** LY2603618
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00988858
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-07
- **Final completion:** 2014-11
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988858, "A Study of Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00988858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*